Lucid Diagnostics Completes $18 Million Stock Offering

Lucid Diagnostics Inc. announced the closing of an $18 million underwritten offering of 18 million common shares at $1.00 per share. The offering was anchored by a $15 million investment from a fundamental institutional investor, with proceeds intended for working capital and corporate purposes. Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners for the offering, which is linked to their commitment to preventing cancer through early detection in at-risk patients.